liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
Karolinska Institute.
Karolinska Institute.
Karolinska Institute.
Aarhus University Hospital.
Show others and affiliations
2010 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 150, no 3, 293-302 p.Article in journal (Refereed) Published
Abstract [en]

Pgreater thanThis prospective Phase II study is the first to assess the feasibility and efficacy of maintenance 5-azacytidine for older patients with high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia and MDS-acute myeloid leukaemia syndromes in complete remission (CR) after induction chemotherapy. Sixty patients were enrolled and treated by standard induction chemotherapy. Patients that reached CR started maintenance therapy with subcutaneous azacytidine, 5/28 d until relapse. Promoter-methylation status of CDKN2B (P15 ink4b), CDH1 and HIC1 was examined pre-induction, in CR and 6, 12 and 24 months post CR. Twenty-four (40%) patients achieved CR after induction chemotherapy and 23 started maintenance treatment with azacytidine. Median CR duration was 13 center dot 5 months, greater than 24 months in 17% of the patients, and 18-30 center dot 5 months in the four patients with trisomy 8. CR duration was not associated with CDKN2B methylation status or karyotype. Median overall survival was 20 months. Hypermethylation of CDH1 was significantly associated with low CR rate, early relapse, and short overall survival (P = 0 center dot 003). 5-azacytidine treatment, at a dose of 60 mg/m2 was well tolerated. Grade III-IV thrombocytopenia and neutropenia occurred after 9 center dot 5 and 30% of the cycles, respectively, while haemoglobin levels increased during treatment. 5-azacytidine treatment is safe, feasible and may be of benefit in a subset of patients.

Place, publisher, year, edition, pages
Blackwell Publishing Ltd , 2010. Vol. 150, no 3, 293-302 p.
Keyword [en]
myelodysplastic syndrome; azacytidine; clinical studies; maintenance therapy; DNA-methylation
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-58201DOI: 10.1111/j.1365-2141.2010.08235.xISI: 000279836800004OAI: diva2:342857
Available from: 2010-08-11 Created: 2010-08-09 Last updated: 2010-08-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Antunovic, Petar
By organisation
Department of Clinical and Experimental MedicineFaculty of Health Sciences
In the same journal
British Journal of Haematology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 42 hits
ReferencesLink to record
Permanent link

Direct link